Segment Information (Tables)

9 Months Ended

Sep. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Profit or Loss and Significant Segment Expenses

Additional information about segment profit or loss and significant segment expenses is as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2025		2024		2025		2024
Direct R&D program expense
BHV-4157 (Troriluzole)	$	10,769	$	14,774	$	38,802	$	48,937
BHV-2000 (Taldefgrobep Alfa)	4,489		20,186		18,719		49,062
BHV-7000 & BHV-7010 (Kv7)	29,671		44,370		92,415		96,575
BHV-2100 & BHV-2110 (TRPM3 Antagonist)	2,720		5,386		26,314		14,278
BHV-8000 (TYK2/JAK1)	4,134		3,064		29,722		9,989
BHV-1300 (IgG Degrader)	8,628		8,745		28,980		25,328
BHV-1310 (IgG Degrader)	369		2,461		5,055		9,659
BHV-1400 (IgA Degrader)	8,049		4,591		19,646		16,295
BHV-1600 (β1-AR AAB Degrader)	1,977		4,145		6,786		7,970
BHV-1510 (TROP-2)	9,327		3,072		19,200		25,700
BHV-1530 (FGFR3)	2,437		—		21,006		—
Other R&D program expense	562		650		2,177		1,680
Preclinical research programs R&D Expense	16,675		13,977		58,608		40,921
R&D personnel expense (excluding share-based compensation)(1)	20,473		18,289		62,100		55,491
R&D Share-based compensation expense	13,947		7,164		62,291		35,526
R&D Knopp amendment expense	—		—		—		171,850
G&A personnel expense (excluding share-based compensation)(1)	6,276		6,288		18,755		18,798
G&A Share-based compensation expense	7,588		4,996		33,118		23,743
Other segment items (2)	21,291		16,010		58,950		43,378
Non-operating loss (income)	3,840		(17,805)		(10,468)		(36,288)
Provision (benefit) for income taxes	221		(59)		1,091		687
Segment net loss	173,443		160,304		593,267		659,579
Reconciliation of profit or loss
Adjustments and reconciling items	—		—		—		—
Consolidated net loss	$	173,443	$	160,304	$	593,267	$	659,579

(1)    Personnel expense includes employee payroll, bonus, and employee benefits for medical care, retirement, insurances and other.

(2)    Other segment items included in Segment net loss include unallocated non-program R&D expense, legal, accounting and other professional service fees, rent and utilities expense, depreciation, and other corporate expenses.